<p>Replimune Group, Inc.（纳斯达克代码：REPL - 获取免费报告）在周五的交易中下跌了 5.9%。该公司的股价最低曾达到 8.91 美元，最后交易价为 8.82 美元。在午盘交易中，共成交了 86,686 股，较平均交易量 931,113 股下降了 91%。该股票此前收盘价为 9.37 美元。</p>
<p>获取 <strong>Replimune Group</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>多位股票分析师最近对该公司发表了评论。HC Wainwright 将 Replimune Group 的价格目标从 21.00 美元上调至 22.00 美元，并在 2 月 13 日的报告中给予该股票 “买入” 评级。摩根大通将 Replimune Group 的股票目标价从 16.00 美元上调至 18.00 美元，并在 2 月 26 日的研究报告中给予该公司 “增持” 评级。七位投资分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “买入”，平均价格目标为 19.43 美元。</p>
<p><strong>查看我们对 REPL 的最新分析</strong></p>
<h2>Replimune Group 股票下跌 6.8%</h2>
<p>该股票的市值为 6.7343 亿美元，市盈率为-2.85，贝塔值为 0.68。该公司的 50 日移动平均价格为 8.42 美元，200 日移动平均价格为 11.11 美元。该公司的速动比率为 11.43，流动比率为 11.43，债务与股本比率为 0.14。</p>
<p>Replimune Group（纳斯达克代码：REPL - 获取免费报告）最近一次公布财报是在 5 月 22 日，报告显示该季度每股收益（EPS）为-0.82 美元，低于分析师共识预期的-0.75 美元，差额为-0.07 美元。去年同期，该公司每股收益为-0.25 美元。分析师预测 Replimune Group, Inc.在当前年度的每股收益将为-2.97 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，内部人士 Konstantinos Xynos 于 5 月 20 日出售了 7,952 股该公司的股票，交易价格为每股 8.06 美元，总交易额为 64,093.12 美元。出售后，该内部人士现在直接持有 146,933 股公司股票，价值 1,184,279.98 美元。这笔交易代表其持股比例下降了 5.13%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，首席会计官 Andrew Schwendenman 于 5 月 20 日出售了 3,287 股公司的股票，交易价格为每股 8.05 美元，总交易额为 26,460.35 美元。出售后，首席会计官现在直接持有 68,284 股公司的股票，价值 549,686.20 美元。这笔交易使其持股比例下降了 4.59%。该出售的披露信息可以在这里找到。过去 90 天内，内部人士已出售 74,907 股公司股票，价值 603,655 美元。公司内部人士持有 8.80% 的股票。</p>
<h2>机构投资者对 Replimune Group 的看法</h2>
<p>机构投资者和对冲基金最近调整了对该公司的持股。Price T Rowe Associates Inc. MD 在第四季度将其在 Replimune Group 的持股增加了 11.0%。Price T Rowe Associates Inc. MD 现在持有该公司 10,962,883 股股票，价值 132,761,000 美元，此前在上个季度又购买了 1,083,633 股。Redmile Group LLC 在第四季度将其在 Replimune Group 的持股增加了 2.6%。Redmile Group LLC 现在持有该公司 4,905,527 股股票，价值 59,406,000 美元，此前在此期间又购买了 124,344 股。先锋集团在第一季度将其在 Replimune Group 的持股增加了 6.6%。先锋集团现在持有该公司 3,833,033 股股票，价值 37,372,000 美元，此前在此期间又购买了 237,185 股。Tang Capital Management LLC 在第四季度将其在 Replimune Group 的持股增加了 125.0%。Tang Capital Management LLC 现在持有该公司 2,700,000 股股票，价值 32,697,000 美元，此前在上个季度又购买了 1,500,000 股。最后，RTW Investments LP 在第四季度将其在 Replimune Group 的持股增加了 82.1%。RTW Investments LP 现在持有该公司 2,065,010 股股票，价值 25,007,000 美元，此前在此期间又购买了 931,223 股。对冲基金和其他机构投资者持有该公司 92.53% 的股票。</p>
<h2>Replimune Group 公司简介</h2>
<p>（获取免费报告）</p>
<p>Replimune Group, Inc.是一家临床阶段的生物技术公司，专注于开发溶瘤免疫疗法以治疗癌症。该公司的专有肿瘤定向溶瘤免疫疗法产品候选者旨在激活免疫系统对抗癌症。其主要产品候选者 RP1 是一种选择性复制的 HSV-1 版本，表达 GALV-GP R(-) 和人类 GM-CSF，目前正在进行针对多种实体肿瘤的 I/II 期临床试验；并已完成针对皮肤鳞状细胞癌的 II 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Replimune Group 更好</li>
<li>现在可以购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>英特尔的转机可能是无人关注的最佳投资</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>3 只将从金色圆顶中获利的防御类股票</li>
<li>什么是 SEC 文件？</li>
<li>ASML 股票可能是这个价格下最安全的芯片投资</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Replimune Group 吗？</h2>
<p>在考虑 Replimune Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Replimune Group 并不在名单上。</p>
<p>虽然 Replimune Group 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

REPL

<p>Replimune Group（纳斯达克代码：REPL）股价下跌 5.9%，至 8.82 美元，交易量较平均水平下降 91%。分析师们的观点不一，HC Wainwright 将其目标价上调至 22 美元，而摩根大通则上调至 18 美元，尽管共识评级仍为 “买入”，平均目标价为 19.43 美元。该公司报告的季度每股收益为（0.82 美元），未能达到预期。内部人士最近出售了股份，机构投资者持有 92.53% 的股份。Replimune 专注于开发用于癌症治疗的溶瘤免疫疗法</p>

<p>Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) traded down 5.9% during trading on Friday . The company traded as low as $8.91 and last traded at $8.82. 86,686 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 931,113 shares. The stock had previously closed at $9.37.</p>
<div class="lb-trans"><p>Replimune Group, Inc.（纳斯达克代码：REPL - 获取免费报告）在周五的交易中下跌了 5.9%。该公司的股价最低曾达到 8.91 美元，最后交易价为 8.82 美元。在午盘交易中，共成交了 86,686 股，较平均交易量 931,113 股下降了 91%。该股票此前收盘价为 9.37 美元。</p>
</div><p>Get <strong>Replimune Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Replimune Group</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of equities analysts have recently commented on the company. HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, February 13th. JPMorgan Chase &amp; Co. raised their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of &#34;Buy&#34; and an average price target of $19.43.</p>
<div class="lb-trans"><p>多位股票分析师最近对该公司发表了评论。HC Wainwright 将 Replimune Group 的价格目标从 21.00 美元上调至 22.00 美元，并在 2 月 13 日的报告中给予该股票 “买入” 评级。摩根大通将 Replimune Group 的股票目标价从 16.00 美元上调至 18.00 美元，并在 2 月 26 日的研究报告中给予该公司 “增持” 评级。七位投资分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “买入”，平均价格目标为 19.43 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on REPL</strong></p>
<div class="lb-trans"><p><strong>查看我们对 REPL 的最新分析</strong></p>
</div><h2>Replimune Group Stock Down 6.8%</h2>
<div class="lb-trans"><h2>Replimune Group 股票下跌 6.8%</h2>
</div><p>The stock has a market capitalization of $673.43 million, a PE ratio of -2.85 and a beta of 0.68. The company's fifty day moving average price is $8.42 and its 200-day moving average price is $11.11. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.</p>
<div class="lb-trans"><p>该股票的市值为 6.7343 亿美元，市盈率为-2.85，贝塔值为 0.68。该公司的 50 日移动平均价格为 8.42 美元，200 日移动平均价格为 11.11 美元。该公司的速动比率为 11.43，流动比率为 11.43，债务与股本比率为 0.14。</p>
</div><p>Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the firm earned ($0.25) EPS. Analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.</p>
<div class="lb-trans"><p>Replimune Group（纳斯达克代码：REPL - 获取免费报告）最近一次公布财报是在 5 月 22 日，报告显示该季度每股收益（EPS）为-0.82 美元，低于分析师共识预期的-0.75 美元，差额为-0.07 美元。去年同期，该公司每股收益为-0.25 美元。分析师预测 Replimune Group, Inc.在当前年度的每股收益将为-2.97 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, insider Konstantinos Xynos sold 7,952 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the sale, the insider now directly owns 146,933 shares in the company, valued at $1,184,279.98. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CAO Andrew Schwendenman sold 3,287 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $26,460.35. Following the sale, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. The trade was a 4.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock worth $603,655 in the last ninety days. 8.80% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Konstantinos Xynos 于 5 月 20 日出售了 7,952 股该公司的股票，交易价格为每股 8.06 美元，总交易额为 64,093.12 美元。出售后，该内部人士现在直接持有 146,933 股公司股票，价值 1,184,279.98 美元。这笔交易代表其持股比例下降了 5.13%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，首席会计官 Andrew Schwendenman 于 5 月 20 日出售了 3,287 股公司的股票，交易价格为每股 8.05 美元，总交易额为 26,460.35 美元。出售后，首席会计官现在直接持有 68,284 股公司的股票，价值 549,686.20 美元。这笔交易使其持股比例下降了 4.59%。该出售的披露信息可以在这里找到。过去 90 天内，内部人士已出售 74,907 股公司股票，价值 603,655 美元。公司内部人士持有 8.80% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Replimune Group</h2>
<div class="lb-trans"><h2>机构投资者对 Replimune Group 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after buying an additional 1,083,633 shares during the last quarter. Redmile Group LLC increased its holdings in shares of Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after purchasing an additional 124,344 shares during the period. Vanguard Group Inc. increased its holdings in shares of Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after purchasing an additional 237,185 shares during the period. Tang Capital Management LLC raised its stake in shares of Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after purchasing an additional 1,500,000 shares during the last quarter. Finally, RTW Investments LP lifted its holdings in shares of Replimune Group by 82.1% in the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after buying an additional 931,223 shares during the period. Hedge funds and other institutional investors own 92.53% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该公司的持股。Price T Rowe Associates Inc. MD 在第四季度将其在 Replimune Group 的持股增加了 11.0%。Price T Rowe Associates Inc. MD 现在持有该公司 10,962,883 股股票，价值 132,761,000 美元，此前在上个季度又购买了 1,083,633 股。Redmile Group LLC 在第四季度将其在 Replimune Group 的持股增加了 2.6%。Redmile Group LLC 现在持有该公司 4,905,527 股股票，价值 59,406,000 美元，此前在此期间又购买了 124,344 股。先锋集团在第一季度将其在 Replimune Group 的持股增加了 6.6%。先锋集团现在持有该公司 3,833,033 股股票，价值 37,372,000 美元，此前在此期间又购买了 237,185 股。Tang Capital Management LLC 在第四季度将其在 Replimune Group 的持股增加了 125.0%。Tang Capital Management LLC 现在持有该公司 2,700,000 股股票，价值 32,697,000 美元，此前在上个季度又购买了 1,500,000 股。最后，RTW Investments LP 在第四季度将其在 Replimune Group 的持股增加了 82.1%。RTW Investments LP 现在持有该公司 2,065,010 股股票，价值 25,007,000 美元，此前在此期间又购买了 931,223 股。对冲基金和其他机构投资者持有该公司 92.53% 的股票。</p>
</div><h2>Replimune Group Company Profile</h2>
<div class="lb-trans"><h2>Replimune Group 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.</p>
<div class="lb-trans"><p>Replimune Group, Inc.是一家临床阶段的生物技术公司，专注于开发溶瘤免疫疗法以治疗癌症。该公司的专有肿瘤定向溶瘤免疫疗法产品候选者旨在激活免疫系统对抗癌症。其主要产品候选者 RP1 是一种选择性复制的 HSV-1 版本，表达 GALV-GP R(-) 和人类 GM-CSF，目前正在进行针对多种实体肿瘤的 I/II 期临床试验；并已完成针对皮肤鳞状细胞癌的 II 期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Replimune Group</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>Intel’s Turnaround May Be the Best Bet No One’s Watching</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>3 Defense Stocks That Will Profit From a Golden Dome</li>
<li>What is a SEC Filing?</li>
<li>ASML Stock Might Be the Safest Chip Play at This Price</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Replimune Group 更好</li>
<li>现在可以购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>英特尔的转机可能是无人关注的最佳投资</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>3 只将从金色圆顶中获利的防御类股票</li>
<li>什么是 SEC 文件？</li>
<li>ASML 股票可能是这个价格下最安全的芯片投资</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Replimune Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Replimune Group 吗？</h2>
</div><p>Before you consider Replimune Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Replimune Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Replimune Group 并不在名单上。</p>
</div><p>While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Replimune Group 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Replimune Group（NASDAQ:REPL）股价下跌 5.9% - 现在是否应该卖出？